Dr Junxian Lim
Dr

Junxian Lim

Email: 
Phone: 
+61 7 334 62386

Background

Junxian Lim is an accomplished molecular biologist at the Institute for Molecular Bioscience. With a strong background in cell biology, protein biochemistry, and pharmacology, he has established himself in the field. Collaborating with researchers at universities, institutions, as well as international industry partners like AstraZeneca and Sosei Heptares, he has contributed significantly to advancing scientific knowledge.

Throughout his doctoral studies, Junxian authored seven ground-breaking studies focused on the development of novel bioactive inhibitors targeting immune cells and inflammatory diseases. These contributions have paved the way for innovative approaches to drug development. Utilizing his expertise, he has successfully developed and characterized a diverse range of protein and cellular assays that enable in-depth investigations into immunity and inflammation. His research findings have been published in prestigious scientific journals, including Nature Communications, Cell Reports, Journal of the American Chemical Society, Diabetes, Journal of Medicinal Chemistry, and the British Journal of Pharmacology. His work has been highly cited, reflecting its impact and significance within the scientific community.

Recognized for his outstanding mentoring abilities, Junxian has supervised or co-supervised the research of two completed PhD students, six completed MPhil students, and three completed Honours students. The success of his former students is a testament to his dedication and guidance. They continue to excel and actively contribute to research endeavours around the world, spanning countries such as Australia, Singapore, Korea, India, Japan, and China.

Beyond his research and mentoring achievements, Junxian actively participates in the scientific community. He serves on the editorial boards of esteemed journals like Journal of Translational Medicine, Frontiers in Molecular Biosciences and Biology. This involvement allows him to stay at the forefront of scientific advancements and contribute to the dissemination of knowledge within his field.

Availability

Dr Junxian Lim is:
Available for supervision
Media expert

Fields of research

Analytical chemistry Bioassays Biological Sciences Biomedical and Clinical Sciences Cell metabolism Chemical Sciences Immunology Pharmacology and pharmaceutical sciences Protein trafficking Receptors and membrane biology Signal transduction

Qualifications

  • Bachelor of Science, The University of Queensland
  • Bachelor (Honours) of Science (Advanced), The University of Queensland
  • Doctor of Philosophy, The University of Queensland
  • Journal Editorial Board Member, Frontiers in Molecular Biosciences, Frontiers in Molecular Biosciences
  • Journal Editorial Board Member, Journal of Translational Medicine, Journal of Translational Medicine
  • Member, Royal Society of Biology, Royal Society of Biology

Research interests

  • Molecular and cellular mechanisms of diseases

    His research focuses on the molecular and cellular mechanisms of diseases, and the development of new therapies. Some of his recent research findings include: - Identification of new therapeutic targets and the development of small molecule inhibitors to target these targets, with the goal of improving current treatments and outcomes - Investigation of the molecular mechanisms that contribute to diseases with the goal of developing novel strategies and improve treatment efficacy

  • Experimental therapeutics for inflammatory diseases and cancers

    Inflammation is a normal physiological response to tissue injury, however uncontrolled inflammation leads to diseases and cancer risk or progression. My current research is focused on developing approaches to better understand the fundamental basis of key proteins involved in uncontrolled inflammation responses and tumourigenesis.

  • Protein-protein interactions

    Protein-protein interactions essentially control all biological functions and are considered as the most basic mechanisms underlying many diseases. Therefore, protein-protein interactions are potential targets in drug development. By merging different approaches in chemistry, biochemistry and pharmacology, we seek to better understand and modulate protein-protein interactions involved in diseases.

Search Professor Junxian Lim’s works on UQ eSpace

44 works between 2009 and 2025
All (44) Journal Article (40) Conference Publication (4)

21 - 40 of 44 works

2019

Conference Publication

Heterocycles for switching GPCR ligand conformation and activity

Fairlie, David, Reid, Robert, Rowley, Jessica, Wu, Kai-Chen, Yau, Mei-Kwan, Lim, Junxian and Iyer, Abishek (2019). Heterocycles for switching GPCR ligand conformation and activity. National Meeting of the American Chemical Society (ACS), Orlando, FL United States, 31 March-4 April 2019. Washington, DC United States: American Chemical Society.

Heterocycles for switching GPCR ligand conformation and activity

2018

Conference Publication

Chemical synthesis and applications of a novel fluorescent probe for human complement C3a receptor

Wu, Chongyang, de Araujo, Aline, Wu, Kai-Chen, Reid, Robert, Durek, Thomas, Lim, Junxian and Fairlie, David (2018). Chemical synthesis and applications of a novel fluorescent probe for human complement C3a receptor. 256th National Meeting and Exposition of the American-Chemical-Society (ACS) - Nanoscience, Nanotechnology and Beyond, Boston Ma, Aug 19-23, 2018. WASHINGTON: AMER CHEMICAL SOC.

Chemical synthesis and applications of a novel fluorescent probe for human complement C3a receptor

2018

Journal Article

Bicyclic helical peptides as dual inhibitors selective for Bcl2A1 and Mcl-1 proteins

de Araujo, Aline D., Lim, Junxian, Wu, Kai-Chen, Xiang, Yibin, Good, Andrew C., Skerlj, Renato and Fairlie, David P. (2018). Bicyclic helical peptides as dual inhibitors selective for Bcl2A1 and Mcl-1 proteins. Journal of Medicinal Chemistry, 61 (7), 2962-2972. doi: 10.1021/acs.jmedchem.8b00010

Bicyclic helical peptides as dual inhibitors selective for Bcl2A1 and Mcl-1 proteins

2018

Journal Article

A potent antagonist of protease-activated receptor 2 that inhibits multiple signaling functions in human cancer cells

Jiang, Yuhong, Yau, Mei-Kwan, Lim, Junxian, Wu, Kai-Chen, Xu, Weijun, Suen, Jacky Y and Fairlie, David P (2018). A potent antagonist of protease-activated receptor 2 that inhibits multiple signaling functions in human cancer cells. The Journal of pharmacology and experimental therapeutics, 364 (2), 246-257. doi: 10.1124/jpet.117.245027

A potent antagonist of protease-activated receptor 2 that inhibits multiple signaling functions in human cancer cells

2017

Journal Article

Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a

Lohman, Rink-Jan, Hamidon, Johan K., Reid, Robert C., Rowley, Jessica A., Yau, Mei-Kwan, Halili, Maria A., Nielsen, Daniel S., Lim, Junxian, Wu, Kai-Chen, Loh, Zhixuan, Do, Anh, Suen, Jacky Y., Iyer, Abishek and Fairlie, David P. (2017). Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a. Nature Communications, 8 (1) 351, 351. doi: 10.1038/s41467-017-00414-w

Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a

2017

Journal Article

Biased signaling by agonists of protease activated receptor 2

Jiang, Yuhong, Yau, Mei-Kwan, Kok, W. Mei, Lim, Junxian, Wu, Kai-Chen, Liu, Ligong, Hill, Timothy A., Suen, Jacky Y. and Fairlie, David P. (2017). Biased signaling by agonists of protease activated receptor 2. ACS Chemical Biology, 12 (5), 1217-1226. doi: 10.1021/acschembio.6b01088

Biased signaling by agonists of protease activated receptor 2

2017

Journal Article

Mapping transmembrane residues of proteinase activated recpetor 2 (PAR2) that influence ligand-modulated calcium signaling

Suen, J.Y., Adams, M. N., Lim, J., Madala, P.K., Xu, W, Cotterell, A., He, Y., Yua, Mei-Kwan, Hooper, J. D. and Fairlie, D.P. (2017). Mapping transmembrane residues of proteinase activated recpetor 2 (PAR2) that influence ligand-modulated calcium signaling. Pharmacological Research, 117, 328-342. doi: 10.1016/j.phrs.2016.12.020

Mapping transmembrane residues of proteinase activated recpetor 2 (PAR2) that influence ligand-modulated calcium signaling

2017

Journal Article

Electrophilic helical peptides that bond covalently, irreversibly, and selectively in a protein-protein interaction site

Dantas De Araujo, Aline, Lim, Junxian, Good, Andrew C., Skerlj, Renato T. and Fairlie, David P. (2017). Electrophilic helical peptides that bond covalently, irreversibly, and selectively in a protein-protein interaction site. ACS Medicinal Chemistry Letters, 8 (1), 22-26. doi: 10.1021/acsmedchemlett.6b00395

Electrophilic helical peptides that bond covalently, irreversibly, and selectively in a protein-protein interaction site

2016

Journal Article

Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists

Seow, Vernon, Lim, Junxian, Cotterell, Adam J., Yau, Mei-Kwan, Xu, Weijun, Lohman, Rink-Jan, Kok, W. Mei, Stoermer, Martin J., Sweet, Matthew J., Reid, Robert C., Suen, Jacky Y. and Farilie, David P. (2016). Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists. Scientific Reports, 6 (1) 24575, 24575.1-24575.12. doi: 10.1038/srep24575

Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists

2016

Journal Article

Protease activated receptor 2 (PAR2) modulators: a patent review (2010–2015)

Yau, Mei-Kwan, Lim, Junxian, Liu, Ligong and Fairlie, David P. (2016). Protease activated receptor 2 (PAR2) modulators: a patent review (2010–2015). Expert Opinion on Therapeutic Patents, 26 (4), 471-483. doi: 10.1517/13543776.2016.1154540

Protease activated receptor 2 (PAR2) modulators: a patent review (2010–2015)

2016

Journal Article

Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activity

Yau, Mei-Kwan, Liu, Ligong, Lim, Junxian, Lohman, Rink-Jan, Cotterell, Adam J., Suen, Jacky Y., Vesey, David A., Reid, Robert C. and Fairlie, David P. (2016). Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activity. Bioorganic and Medicinal Chemistry Letters, 26 (3), 986-991. doi: 10.1016/j.bmcl.2015.12.048

Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activity

2016

Journal Article

PAR2 modulators derived from GB88

Yau, Mei-Kwan, Liu, Ligong, Suen, Jacky Y., Lim, Junxian, Lohman, Rink-Jan, Jiang, Yuhong, Cotterell, Adam J., Barry, Grant D., Mak, Jeffrey Y. W., Vesey, David A., Reid, Robert C. and Fairlie, David P. (2016). PAR2 modulators derived from GB88. ACS Medicinal Chemistry Letters, 7 (12), 1179-1184. doi: 10.1021/acsmedchemlett.6b00306

PAR2 modulators derived from GB88

2016

Journal Article

Potent small agonists of protease activated receptor 2

Yau, Mei-Kwan, Suen, Jacky Y., Xu, Weijun, Lim, Junxian, Liu, Ligong, Adams, Mark N., He, Yaowu, Hooper, John D., Reid, Robert C. and Fairlie, David P. (2016). Potent small agonists of protease activated receptor 2. ACS Medicinal Chemistry Letters, 7 (1), 105-110. doi: 10.1021/acsmedchemlett.5b00429

Potent small agonists of protease activated receptor 2

2015

Journal Article

Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2

Xu, Weijun, Lim, Junxian, Goh, Chai-Yeen, Suen, Jacky Y., Jiang, Yuhong, Yau, Mei-Kwan, Wu, Kai-Chen, Liu, Ligong and Fairlie, David P. (2015). Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2. Journal of Chemical Information and Modeling, 55 (10), 2079-2084. doi: 10.1021/acs.jcim.5b00500

Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2

2015

Conference Publication

Potent small agonists of protease activated receptor 2

Yau, Mei Kwan, Suen, Jacky, Xu, Weijun, Lim, Junxian, Liu, Ligong, Adams, Mark, He, Yaowu, Hooper, John, Reid, Robert and Fairlie, David (2015). Potent small agonists of protease activated receptor 2. WASHINGTON: AMER CHEMICAL SOC.

Potent small agonists of protease activated receptor 2

2015

Journal Article

Three homology models for PAR2 derived from different templates: Application to antagonist discovery

Perry, Samuel R., Xu, Weijun, Wirija, Anna, Lim, Junxian, Yau, Mei-Kwan, Stoermer, Martin J., Lucke, Andrew J. and Fairlie, David P. (2015). Three homology models for PAR2 derived from different templates: Application to antagonist discovery. Journal of Chemical Information And Modeling, 55 (6), 1181-1191. doi: 10.1021/acs.jcim.5b00087

Three homology models for PAR2 derived from different templates: Application to antagonist discovery

2015

Conference Publication

Downsizing Proteins Without Losing Potency or Function

Fairlie, David P. , Yau, Mei-Kwan , Hamidon, Johan K. , Singh, Ranee , Lim, Junxian , Suen, Jacky Y. , Rowley, Jessica A. , Lohman, Rink-Jan , Stoermer, Martin J. , Iyer, Abishek and Reid, Robert C. (2015). Downsizing Proteins Without Losing Potency or Function. American Peptide Symposium 2015, Orlando , Florida, United States, 20-25 June 2015. American Peptide Society. doi: 10.17952/24APS.2015.016

Downsizing Proteins Without Losing Potency or Function

2014

Journal Article

Potent heterocyclic ligands for human complement C3a receptor

Reid, Robert C., Yau, Mei-Kwan, Singh, Ranee, Hamidon, Johan K., Lim, Junxian, Stoermer, Martin J. and Fairlie, David P. (2014). Potent heterocyclic ligands for human complement C3a receptor. Journal of Medicinal Chemistry, 57 (20), 8459-8470. doi: 10.1021/jm500956p

Potent heterocyclic ligands for human complement C3a receptor

2014

Journal Article

Pathway-selective antagonism of proteinase activated receptor 2

Suen, J. Y., Cotterell, A., Lohman, R. J., Lim, J., Han, A., Yau, M. K., Liu, L., Cooper, M. A., Vesey, D. A. and Fairlie, D. P. (2014). Pathway-selective antagonism of proteinase activated receptor 2. British Journal of Pharmacology, 171 (17), 4112-4124. doi: 10.1111/bph.12757

Pathway-selective antagonism of proteinase activated receptor 2

2013

Journal Article

Inflammatory Responses Induced by Lipopolysaccharide Are Amplified in Primary Human Monocytes but Suppressed in Macrophages by Complement Protein C5a

Seow, Vernon, Lim, Junxian, Iyer, Abishek, Suen, Jacky Y., Ariffin, Juliana K., Hohenhaus, Daniel M., Sweet, Matthew J. and Fairlie, David P. (2013). Inflammatory Responses Induced by Lipopolysaccharide Are Amplified in Primary Human Monocytes but Suppressed in Macrophages by Complement Protein C5a. Journal of Immunology, 191 (8), 4308-4316. doi: 10.4049/jimmunol.1301355

Inflammatory Responses Induced by Lipopolysaccharide Are Amplified in Primary Human Monocytes but Suppressed in Macrophages by Complement Protein C5a

Availability

Dr Junxian Lim is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Available projects

  • Protein-protein interactions

    Protein-protein interactions are key to the regulation of biological processes in all forms of life and in disease. Our group seeks to understand complex protein-protein interactions that have traditionally thought to be “undruggable”. Projects are avaliable to investigate novel proteins, signalling pathways and molecules using advanced imaging and microscopy, protein biochemistry, cell-based assays, peptide synthesis and NMR spectroscopy.

    Projects include

    • Drug design and discovery (peptide synthesis, peptidomimetics, in silico-assisted, NMR structure, dynamics)
    • Drug mechanisms of action (cell biology, signalling pathways, enzymology, GPCRs)
    • Pharmacology (rodent models of inflammatory diseases)

  • Therapeutics for inflammatory diseases and cancers

    Our group investigates molecular mechanisms of chemical reactions, biological processes, disease development and drug action. My team seeks to understand various aspects of inflammation, from mediators and signaling pathways to therapeutic opportunities. Projects are avaliable to investigate new approaches to modulate G-protein coupled receptors (GPCRs) signalling, cell & molecular biology or pharmacology (animal models of inflammatory diseases, allergies & asthma, cancers).

    Projects include

    • Molecular pharmacology (ligand binding, ligand potency, receptor mutagenesis, in silico modelling and docking)
    • Bioactive peptides and peptide-based drug discovery (peptide synthesis, NMR spectroscopy, microscopy and flow cytometry)

Supervision history

Current supervision

  • Doctor Philosophy

    G protein-coupled Receptors in Colon and Kidney Cancer

    Principal Advisor

    Other advisors: Professor David Fairlie

  • Doctor Philosophy

    Modulation of innate immune proteins in cancers

    Principal Advisor

    Other advisors: Professor David Fairlie

  • Doctor Philosophy

    Therapeutic strategies to inhibit oncogenic transcription factors

    Associate Advisor

    Other advisors: Dr Tim Hill, Professor David Fairlie

  • Doctor Philosophy

    Peptide modulators for drug discovery

    Associate Advisor

    Other advisors: Professor David Fairlie

  • Master Philosophy

    Mechanisms of GPCR activation

    Associate Advisor

    Other advisors: Professor David Fairlie

  • Doctor Philosophy

    Developing a new type of drug for inflammatory disease

    Associate Advisor

    Other advisors: Professor David Fairlie

  • Doctor Philosophy

    Glucose and lipid metabolism and mechanism study of active compounds.

    Associate Advisor

    Other advisors: Professor David Fairlie

  • Master Philosophy

    ß-arrestin and G protein signalling by C3aR and PAR2

    Associate Advisor

    Other advisors: Professor David Fairlie

Completed supervision

Enquiries

Contact Dr Junxian Lim directly for media enquiries about:

  • biology
  • cancer
  • GPCR
  • in-vitro protein labeling
  • inflammation
  • metabolic dysfunction
  • obesity
  • pharmacology
  • protein-protein interactions

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au